Yale Researchers Crack the Code of a Rare, Inherited Anemia
Yale pediatrician and geneticist Patrick Gallagher, M.D., studies hereditary spherocytosis (HS), an inherited disease associated with hemolytic anemia, when red blood cells are destroyed faster than they are produced due to abnormal membranes. A novel mutation in the gene that encodes alpha-spectrin, a protein essential for normal red blood cell membranes, is responsible for many cases of recessive hereditary spherocytosis (rHS), the most severe form of the disease, reports Gallagher’s team
Yale Cancer Center Researchers Identify New T cell Subsets with Potential to Improve Cellular Therapy for Cancer
A Yale Cancer Center research team has identified that two genes, NR4A1 and ABC transporters, mark a distinct subset of quiescent T cells within human tissues, and have developed methods to mobilize them into circulation for potential application in adoptive T cell therapy of cancer.
Convalescent Plasma for Severe COVID-19: D-Dimer Level After Transfusion May Be a Predictive Biomarker of Mortality
Researchers characterized the outcomes seen in patients hospitalized with severe coronavirus disease 2019 (COVID-19) after infusion with convalescent plasma (CP), and the results were presented during the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.Source: Cancer Therapy Advisor
Amer Zeidan, MBBS, MHS, Discusses Efficacy of Azacitdine Plus Durvalumab for AML and MDS
At the 2019 ASH Annual Meeting, Amer M. Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, Connecticut, discusses results from a large, international, randomized phase 2 study exploring azacitidine plus durvalumab for older patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) who are unfit for intensive chemotherapy.Source: Oncology Learning Network
Yale Cancer Center researchers show identifying type of chronic pain in adults with sickle cell disease may lead to better outcomes
Identifying the type of pain an adult with sickle cell disease (SCD) experiences may be useful in improving treatment, according to a new study by researchers at Yale Cancer Center (YCC) and Smilow Cancer Hospital.
Department of Neurology Receives Major Grant to Evaluate Blood Thinners and Stroke Prevention
Yale School of Medicine has received a 5-year, $20 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) to administer a Phase III trial measuring the effectiveness of using a blood thinner to prevent new strokes in patients who suffered brain hemorrhages and have atrial fibrillation, or irregular heartbeat.
Smilow Cancer Hospital and Yale Cancer Center receive grant from Frederick A. DeLuca Foundation to fund Hematology Research Center
Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) are proud to announce a five-year grant awarded by The Frederick A. DeLuca Foundation to establish The DeLuca Center for Innovation in Hematology Research.
Pediatric Hematologist Presents on Rare Leukemia
At the Hematology Research Seminar Friday, August 3, Nina Kadan-Lottick, MD, associate professor of pediatrics (hematology/oncology), presented research on a rare form of leukemia to scientists and adult oncologists, an audience of potential collaborators.
Stahl honored at 59th American Society of Hematology Annual Meeting
For the second consecutive year, Yale Cancer Center (YCC) researcher Maximilian Stahl, M.D., was awarded an American Society of Hematology (ASH) Abstract Achievement award. Besides working at YCC, Stahl is one of five Internal Medicine Traditional Residency Program Chiefs at Yale School of Medicine. He received the ASH award for his abstract titled, “The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center Analysis”. The ASH Abstract Achievement Award is a merit-based award for trainees with high-scoring annual meeting abstracts.
Madhav Dhodapkar Receives Prestigious Outstanding Investigator Award
The National Cancer Institute (NCI) has named Madhav V. Dhodapkar, MBBS, a recipient of its Outstanding Investigator Award. Dr. Dhodapkar is the Arthur H. Bunker and Isabel Bunker Professor of Medicine (Hematology), Chief of Hematology, Professor of Immunobiology, and co-Director of the Cancer Immunology Program of Yale Cancer Center. He will receive $7 million in research funding over seven years from the NCI.